english.prescrire.org > Prescrire International > N°68 - December 2003

n°68

December 2003

Issue Contents
Editorial

Appearances can be deceptive

p.202

New Products


Memantine: poor evaluation and uncertain benefit in Alzheimer's disease

p.203-205

Psychometric scales in dementia

p.205

Pegylated interferon: chronic hepatitis C: advantageous for some patients, but more data needed

p.206-210

Liposomes, pegylation, and pegylated liposomes

p.209

Paracetamol + tramadol: no advance

p.211-213

Tadalafil: slightly more convenient, but poorly assessed in organic disorders

p.213-215

Imatinib: chronic myeloid leukaemia, first-line option: favourable findings to be confirmed

p.216-218

Imatinib and second-line treatment of chronic myeloid leukaemia: what long-term effects?

p.217

Type B botulinum toxin

p.219

Intravenous iron

p.219

Telmisartan + hydrochlorothiazide

p.219

Adverse Effects


Adverse effects of BCG vaccination

p.220-224

Glitazones and hepatitis and cardiac risks (continued)

p.225

Valvular heart disease with pergolide

p.225

Serious cutaneous reactions to amifostine

p.225

Neuropsychiatric adverse effects: coxibs too

p.225

Reviews


Intradermal BCG: partial protection against tuberculosis in children; unproven efficacy of multipuncture administration

p.226-229

Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease

p.230-231

Outlook


Drug advertising: the smokescreen of bibliographic references

p.232

Clinical guidelines are not immortal

p.233-234

Data protection: an anti-generic weapon

p.235

Heroin prescription in Europe

p.235-236

Errors in ambulatory medicine: research is in its infancy

p.236-237

Forum


Prevention of pulmonary embolism (continued)

p.238-239

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe